ESTEVE Expands U.S. Market Presence with Acquisition of TerSera's Business Unit

ESTEVE, a global pharmaceutical company based in Barcelona, has announced the acquisition of TerSera Therapeutics' Infusion Specialty Therapies Business Unit. The move marks a strategic expansion of ESTEVE's presence in the U.S., featuring two highly specialized medications: Prialt® and Quzyttir®. Prialt®, a non-opioid FDA-approved treatment for severe chronic pain, and Quzyttir®, an H1 antihistamine for acute urticaria, will now augment ESTEVE's portfolio.

CEO Staffan Schüberg expressed enthusiasm over integrating TerSera’s assets and team, aligning with ESTEVE’s goal to address unmet medical needs. The acquisition also consolidates ESTEVE’s global rights for Quzyttir®, except in China. The deal, expected to close in Q1 2026, is supported by financial advisories from Perella Weinberg Partners and legal counsel from Arnold & Porter.